A groundbreaking development in the fight against HIV is poised to transform global health. Lenacapavir, a twice-yearly injectable HIV prevention drug (PrEP), will be available at a drastically reduced cost in 120 low- and middle-income countries starting in 2027. This significant price drop, to just $40 per patient annually, is a result of agreements between Gilead Sciences, the drug's originator, and six generic drug manufacturers. This makes lenacapavir comparable in cost to daily oral PrEP pills, addressing a major access barrier.
The World Health Organization (WHO) has hailed lenacapavir as a 'next best thing' to an HIV vaccine, highlighting its remarkable effectiveness in clinical trials. Its six-monthly injection frequency offers a significant advantage over daily pills, addressing adherence challenges linked to stigma and practical difficulties.
Funding partnerships between organizations like Unitaid, the Clinton Health Access Initiative (Chai), the Gates Foundation, and the Wits Reproductive Health and HIV Institute (Wits RHI) have been instrumental in securing this affordable pricing. These collaborative efforts demonstrate a commitment to equitable access to essential medicines in regions most impacted by the HIV epidemic.
While this affordable access is a major victory, challenges remain. The 2027 rollout date is still some time away, and concerns persist regarding access in countries not included in the initial 120. Further investment is crucial to bridge this gap and ensure that vulnerable populations – including men who have sex with men, sex workers, people who use drugs, and prisoners – have access to lenacapavir. The ongoing funding crisis for HIV initiatives adds another layer of complexity.
Former US President Bill Clinton, co-founder of Chai, described the lenacapavir rollout as "a genuine chance to end" the global HIV epidemic. However, this ambitious goal necessitates sustained commitment and investment to overcome existing barriers and ensure that this life-saving drug reaches those who need it most. The successful collaboration between Gilead, generic manufacturers, and global health organizations offers a beacon of hope for a future where HIV is no longer a global health crisis.
---
Originally published at: https://www.theguardian.com/society/2025/sep/24/hiv-prevention-jab-pre-exposure-prophylaxis-prep-lenacapavir-120-poorer-countries-2027
